TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
IRWD

Ironwood Pharmaceuticals Inc

Healthcare · Drug Manufacturers - Specialty & Generic

4.20$ +1.4% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Ironwood Pharmaceuticals Inc (IRWD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.8% of the shares are freely tradable; institutional investors hold 98.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 98.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 3.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 82.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 11.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 165Mio.

Largest Shareholders

Institutions

Institutions IRWD
Name Stake (%) Shares Change (%) Date
Armistice Capital, LLC 9.09 15,028,000 -6.2 03/31/2026
BlackRock Inc 8.09 13,362,930 +4.5 03/31/2026
Sarissa Capital Management LP 5.56 9,188,635 +0.0 06/30/2026
Bank of America Corp 5.25 8,682,907 -24.6 03/31/2026
Renaissance Technologies Corp 4.88 8,061,073 -1.8 03/31/2026
AQR Capital Management LLC 4.56 7,535,080 +59.5 03/31/2026
State Street Corp 4.51 7,456,944 +69.0 03/31/2026
Vanguard Portfolio Management, LLC 4.04 6,682,037 +0.0 03/31/2026
Acadian Asset Management LLC 3.98 6,577,272 +2,378.7 03/31/2026
Vanguard Capital Management, LLC 3.69 6,097,454 +0.0 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings IRWD
Person Role Shares Value As of Type
Silver Ronald PFO & PAO 313,680 1,317,456 $ Jul 7, 2026 direct
Silber Jeffrey SVP, CMO, Head-Res&Drug 137,036 575,551 $ Jul 20, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Jul 20, 2026 Silber Jeffrey SVP, CMO, Head-Res&Drug Other 137,036 0.00
Jul 7, 2026 Silver Ronald PFO & PAO Sell 127,890 4.52 578,063

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?